Augustina Isioma Ikusemoro: Is Blood Really Affordable?
Augustina Isioma Ikusemoro, Hematology and Transfusion Medicine Specialist at Sharjah Blood Transfusion and Research Center, shared a post on LinkedIn:
“In many LMICs, families must pay out of pocket for blood transfusions – often at the worst moment of their lives.
Behind every ‘unit’ of blood lies:
- Testing
- Processing
- Cold storage
- Transport
- Skilled expertise
Safe blood saves lives — but it isn’t cheap to produce.
The real tragedy?
- People don’t die because blood doesn’t exist.
- They die because they can’t afford it.
No woman should bleed to death in childbirth.
No child should die of treatable anemia.
No trauma victim should be denied transfusion because of cost.
- Safe blood must be treated as a public health necessity — not a market commodity.
Universal Health Coverage is incomplete without universal access to safe blood.
The Way Forward
Countries that have transformed blood safety share common solutions:
- Strong centralized national blood services
- Government financing and policy commitment
- Universal access models (blood as a public good)
- Investment in infrastructure and workforce
- Robust donor recruitment systems
- Integration into national health insurance schemes
Safe blood systems do not emerge by chance — they are built through leadership, policy, and sustained investment.
- We must stop asking whether blood is expensive.
- We must start asking why patients are the ones paying the price.
Blood is not just a product.
It is a critical component of health system resilience.
And in emergencies, it is the difference between life and death.
If your country still relies heavily on out-of-pocket payments for blood transfusion, what reforms do you believe are most urgent?
Let’s move this conversation from awareness to policy to action.”
Stay updated with Hemostasis Today.
-
Mar 9, 2026, 16:26Todd Maderis: Great Conversation on Effective Treatment of Chronic Infections
-
Mar 9, 2026, 16:25Denise Braendgaard: How Partnership is Turning Ambition Into Action
-
Mar 9, 2026, 16:10Veronica Sanchez: Recognizing the Risks of Preeclampsia During Pregnancy and Newly Postpartum
-
Mar 9, 2026, 16:06Abdul Mannan: Explaining the Molecular Mechanism Behind VITT
-
Mar 9, 2026, 16:03Wathsala Manindrani: Managing Severe Hypertriglyceridemia in Resource-Limited Settings
-
Mar 9, 2026, 15:55Honoring the Volunteers, Advocates, and Families Driving Awareness and Research of Glanzmann Thrombasthenia – GRF
-
Mar 9, 2026, 15:50Filippo Mazzi: IVIG as an Alternative Therapy for Acute Chest Syndrome in Patients with Sickle Cell Disease
-
Mar 9, 2026, 15:45llenia Calcaterra: Women’s Empowerment Through Autonomy, Education, and Financial Independence
-
Mar 9, 2026, 15:36Alyaa Al-Mughairy: Rethinking Emicizumab Low-Dose Regimens to Ensure Safe and Sustainable Patient Access